{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:56:51Z","timestamp":1792699011563,"version":"4.5.0"},"reference-count":67,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2451526","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T07:30:31Z","timestamp":1736407831000},"page":"196-206","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England &amp; Wales: results of the FINE-CKD model"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David","family":"Cherney","sequence":"first","affiliation":[{"name":"University Health Network, University of Toronto","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Drzewiecka","sequence":"additional","affiliation":[{"name":"Putnam","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Folkerts","sequence":"additional","affiliation":[{"name":"Bayer AG","place":["Wuppertal, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-2255","authenticated-orcid":false,"given":"Pierre","family":"Levy","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019Economie de Dauphine, Universit\u00e9 Paris-Dauphine, Universit\u00e9 Paris Sciences et Lettres","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Millier","sequence":"additional","affiliation":[{"name":"Clever-Access","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-3563","authenticated-orcid":false,"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, University of Cambridge","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Pochopie\u0144","sequence":"additional","affiliation":[{"name":"Clever-Access","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-7302","authenticated-orcid":false,"given":"Prabir","family":"Roy-Chaudhury","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina","place":["Chapel Hill, USA"]},{"name":"WG (Bill) Hefner Department Salisbury Veterans Affairs Medical Center","place":["Salisbury, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-6540","authenticated-orcid":false,"given":"Sean D.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics Institute and School of Pharmacy, University of Washington","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5939-973X","authenticated-orcid":false,"given":"Paul","family":"Mernagh","sequence":"additional","affiliation":[{"name":"Bayer AG","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.17379"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2015-000154"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.73"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01674-7"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040947"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800256"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14225"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs269"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-71"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/ijnrd.s58074"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204639"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30097-9"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02234-2"},{"key":"e_1_3_4_16_1","unstructured":"Public Health England. Guidance: health matters \u2013 preventing type 2 diabetes. [cited 2022 Oct 31]. Available from: https:\/\/www.gov.uk\/government\/publications\/health-matters-preventing-type-2-diabetes\/health-matters-preventing-type-2-diabetes"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.17925\/ee.2021.17.2.84"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.02.030"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1059819"},{"key":"e_1_3_4_21_1","unstructured":"National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline [NG28]. NICE; [cited 2022 Aug 8]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/type-2-diabetes-in-adults-management-pdf-1837338615493"},{"key":"e_1_3_4_22_1","unstructured":"National Institute for Health and Care Excellence (NICE). Appraisal consultation document: finerenone for treating chronic kidney disease in type 2 diabetes. [cited 2022 Oct 31]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta877"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503713"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503712"},{"key":"e_1_3_4_26_1","unstructured":"FDA. KERENDIA (finerenone) [package insert]. [cited 2022 Oct 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215341s000lbl.pdf"},{"key":"e_1_3_4_27_1","unstructured":"Kerendia 10\u2009mg film coated tablets. Electronic Medicines CompendiumEMC; [updated 2022 Mar 21; cited 2022 Aug 8]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/13437\/smpc"},{"key":"e_1_3_4_28_1","unstructured":"EMA. Summary of product characteristics. [cited 2022 Oct 31]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kerendia-epar-product-information_en.pdf"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2018.00328"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2019.02.009"},{"key":"e_1_3_4_31_1","unstructured":"Centre of Innovation in Regulatory Science. Mapping of HTA in Europe \"regulatory and reimbursement atlas\". [cited 2022 Oct 31]. Available from: https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/ev_20160520_co07_en_0.pdf"},{"key":"e_1_3_4_32_1","unstructured":"Guide to the methods of technology appraisal 2013. Process and methods [PMG9]. NICE; [cited 2022 Aug 8]. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781"},{"key":"e_1_3_4_33_1","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. [cited 2022 Oct 31]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741"},{"key":"e_1_3_4_34_1","unstructured":"Scottish Medicines Consortium. Working with SMC \u2013 a guide for manufacturers. [cited 2022 Oct 31]. Available from: https:\/\/scottishmedicines.org.uk\/media\/8208\/working-with-smc.pdf"},{"key":"e_1_3_4_35_1","unstructured":"All Wales Medicines Strategy Group (AWMSG). AWMSG in relation to NICE. [cited 2022 Oct 31]. Available from: https:\/\/awttc.nhs.wales\/accessing-medicines\/make-a-submission\/pharmaceutical-industry-submissions\/submit-for-awmsg-appraisal\/invisible\/awmsg-in-relation-to-nice1\/"},{"issue":"6","key":"e_1_3_4_36_1","first-page":"S104","article-title":"Validation of the FINE-CKD model for future health technology assessments for finerenone in patients with chronic kidney disease and type 2 diabetes","volume":"28","author":"Pochopie\u0144 M","year":"2022","unstructured":"Pochopie\u0144 M, Cherney D, Aleksandra Drzewiecka M, et\u00a0al. Validation of the FINE-CKD model for future health technology assessments for finerenone in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care. 2022;28(6):S104\u2013S111.","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88808"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"e_1_3_4_39_1","unstructured":"NHS Business Services Authority. Dictionary of medicines and devices (dm+d). [2022 Aug 8]. Available from: https:\/\/www.nhsbsa.nhs.uk\/pharmacies-gp-practices-and-appliance-contractors\/dictionary-medicines-and-devices-dmd."},{"key":"e_1_3_4_40_1","unstructured":"Joint Formulary Committee. British National Formulary (online). London (UK): BMJ and Pharmaceutical Press; 2023 [cited 2023 Jul 24]. Available from: http:\/\/www.medicinescomplete.com"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0054-0"},{"key":"e_1_3_4_42_1","unstructured":"Tolvaptan for treating autosomal dominant polycystic kidney disease. Technology appraisal guidance [TA358]. NICE; [cited 2022 Aug 8]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta358\/resources\/tolvaptan-for-treating-autosomal-dominant-polycystic-kidney-disease-pdf-82602675026629"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12647"},{"key":"e_1_3_4_44_1","unstructured":"Unit Costs of Health and Social Care. Personal Social Services Research Unit (PSSRU); 2020 [cited 2022 Aug 8]. Available from: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2020\/"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3564"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz106.FP374"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001037"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1_3"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.014"},{"key":"e_1_3_4_50_1","first-page":"x","volume-title":"Decision modelling for health economic evaluation","author":"Briggs AH","year":"2007","unstructured":"Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Reprinted 2007 with corrections, 2011. ed. Oxford handbooks in health economic evaluation. Oxford (UK): Oxford University Press; 2007. p. x, 237."},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X03255922"},{"key":"e_1_3_4_52_1","unstructured":"Ara R Wailoo AJ. NICE DSU Technical Support Document 12: the use of health state utility values in decision models; 2011. Available from: http:\/\/www.nicedsu.org.uk"},{"key":"e_1_3_4_53_1","unstructured":"Chronic kidney disease: assessment and management. NICE guideline [NG203]. NICE; [cited 2022 May 8]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng203\/resources\/chronic-kidney-disease-assessment-and-management-pdf-66143713055173"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"e_1_3_4_55_1","unstructured":"Herrington WG. FA. UK kidney association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease. Available from: https:\/\/guidelines.ukkidney.org\/"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102426"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0903-4"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0294"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_3_4_60_1","unstructured":"UK Renal Registry 22nd Annual Report. Data to 31\/12\/2018. UK Kidney Association. Accessed 2022 Aug 8."},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.10.008"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x12454577"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067975"},{"key":"e_1_3_4_64_1","unstructured":"Farmer C Irving J Karunaratne K. What does it actually cost to improve population blood pressure control? Abstract. 2011."},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12312"},{"key":"e_1_3_4_66_1","unstructured":"(CDA-AMC) CDA. Finerenone. [cited 2022 Oct 31]. Available from: https:\/\/www.cda-amc.ca\/finerenone"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02053-6"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15997"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2451526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:48:17Z","timestamp":1766400497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2451526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2451526"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2451526","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}